- Home
- BRT vs AQST Comparison
BRT vs AQST Comparison
Compare BRT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- AQST
- Stock Information
- Founded
- BRT 1972
- AQST 2004
- Country
- BRT United States
- AQST United States
- Employees
- BRT N/A
- AQST N/A
- Industry
- BRT Real Estate Investment Trusts
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- AQST Health Care
- Exchange
- BRT Nasdaq
- AQST Nasdaq
- Market Cap
- BRT 291.9M
- AQST 272.9M
- IPO Year
- BRT N/A
- AQST 2018
- Fundamental
- Price
- BRT $15.62
- AQST $4.07
- Analyst Decision
- BRT Strong Buy
- AQST Strong Buy
- Analyst Count
- BRT 1
- AQST 7
- Target Price
- BRT $21.00
- AQST $11.29
- AVG Volume (30 Days)
- BRT 34.5K
- AQST 1.3M
- Earning Date
- BRT 08-05-2025
- AQST 08-05-2025
- Dividend Yield
- BRT 6.39%
- AQST N/A
- EPS Growth
- BRT N/A
- AQST N/A
- EPS
- BRT N/A
- AQST N/A
- Revenue
- BRT $98,162,000.00
- AQST $54,228,000.00
- Revenue This Year
- BRT $0.36
- AQST N/A
- Revenue Next Year
- BRT $5.65
- AQST $45.71
- P/E Ratio
- BRT N/A
- AQST N/A
- Revenue Growth
- BRT 2.71
- AQST 5.29
- 52 Week Low
- BRT $14.61
- AQST $2.12
- 52 Week High
- BRT $20.22
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- BRT 49.47
- AQST 72.86
- Support Level
- BRT $15.72
- AQST $3.62
- Resistance Level
- BRT $16.20
- AQST $3.80
- Average True Range (ATR)
- BRT 0.40
- AQST 0.19
- MACD
- BRT -0.01
- AQST 0.05
- Stochastic Oscillator
- BRT 49.43
- AQST 95.43
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.